Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.

Therapies for patients with unresectable hepatocellular carcinoma (uHCC) are currently popular. Current first-line standard-of-care treatments for uHCC are systematic therapies. However, treatments that combine locoregional therapy with systemic therapy are widely accepted in China and have demonstrated high rates of tumor response and conversion to resection with manageable toxicity. A literature review was performed by searching published literature in PubMed and Web of Science up to December 2023 for relevant articles on the use of triple therapy (transarterial chemoembolization combined with lenvatinib and anti-PD-1 antibodies) in uHCC. This review concentrates on the efficacy and safety of triple therapy with Chinese characteristics in patients with uHCC and describes the outcome of conversion surgery, degree of pathological necrosis, and effect prediction. This article will contribute to a comprehensive understanding of the role of triple therapy with Chinese characteristics in patients with uHCC.

Fabrication of the hollow dodecahedral NiCoZn layered double hydroxide for high-performance flexible asymmetric supercapacitor.

Layered double hydroxides (LDHs) with unique layered structure have excellent theoretical capacitance. Nevertheless, the constrained availability of electrically active sites and cationic species curtails their feasibility for practical implementation within supercapacitors. Most of the reported materials are bimetallic hydroxides, and fewer studies are on trimetallic hydroxides. In here, the hollow dodecahedron NiCoZn-LDH is synthesized using CoZn metal-organic frameworks (CoZn-MOFs) as template. Its morphology and composition are studied in detail. Concurrently, the effect of the amount of third component on the resulting structure of NiCoZn-LDH is also researched. Benefiting from its favorable structural and compositional attributes to efficient transfer of ions and electrons, NiCoZn-LDH-200 demonstrates outstanding specific capacitance of 1003.3F g-1 at 0.5 A/g. Furthermore, flexible asymmetric supercapacitor utilizing NiCoZn-LDH-200 as the positive electrode and activated carbon (AC) as the negative electrode reveals favorable electrochemical performances, including a notable specific capacitance of 184.7F g-1 at 0.5 A/g, a power density of 368.21 W kg-1 at a high energy density of 65.66 Wh kg-1, an energy density of 31.78 Wh kg-1 at a high power density of 3985.97 W kg-1, a capacitance retention of 92 % after 8000 cycles at 5 A/g, and a good capacitance retention of 90 % after 500 cycles of bending. The template method presented herein can effectively solve the problem of easy accumulation and improve the electrochemical properties of the materials, which exhibits a broad research prospect.

Fabrication of hollow core-shell NiCo2O4@polypyrrole nanofibers/reduced graphene oxide ternary composites with excellent microwave absorption performances.

In contemporary times, electromagnetic radiation poses a significant threat to both human health and the normal functioning of electronic devices. Developing composites as adsorption materials possess exceptional electromagnetic wave absorption performances can efficient address this critical issue. Herein, hollow core-shell NiCo2O4@polypyrrole nanofibers/reduced graphene oxide (NiCo-HFPR) composites are fabricated by the combination of electrostatic spinning, air calcination, in-situ polymerization, freeze-drying and hydrazine vapor reduction. As anticipated, NiCo-HFPR-0.2 exhibits noteworthy properties, with the minimum reflection loss (RLmin) of -61.20 dB at 14.26 GHz and 1.56 mm, as well as the effective absorption bandwidth (EAB) of 4.90 GHz at 1.57 mm. Additionally, the simulation procedure is employed to determine the radar cross-section (RCS) attenuation. In comparison to a singular perfect electrically conductive (PEC) layer, the PEC layer coated with NiCo-HFPR-0.2 consistently yields an RCS value below -10 dB m2 within the range of -60° < θ < 60°. The RCS attenuation value of the NiCo-HFPR-0.2 coating achieves an outstanding 31.0 dB m2 at θ = 0°, strongly affirming the ability to effectively attenuate electromagnetic wave in real-world applications. The employed experimental methodology, the meticulously crafted composite, and the simulation outcomes presented in this study bear great promise for the progressive advancement of both theoretical investigations and practical applications within the domain of electromagnetic wave absorption.

Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.

Purpose: Few reliable biomarkers for predicting the efficacy of triple therapy (lenvatinib + immune checkpoint inhibitors + transarterial chemoembolization) exist for patients with unresectable hepatocellular carcinoma (uHCC). This study explored the prognostic role of alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) levels in patients with uHCC receiving triple therapy. Patients and Methods: This retrospective study included 93 patients with uHCC who received triple therapy at Fujian Provincial Hospital between August 2020 and November 2022. Depending on the respective baseline levels, the patients were divided into high-AFP and high-DCP groups. An early response was defined as an AFP or DCP concentration >50% less than the baseline concentration after 6 weeks of triple therapy. The primary endpoint was the objective response rate (ORR). The secondary endpoints were progression-free survival (PFS) and overall survival (OS). Results: After 6 weeks of triple therapy, 75.3% (58/77) and 78.9% (60/76) of patients in the high-AFP and high-DCP groups achieved an objective response. Early AFP and DCP responses were positively associated with ORR (high-AFP group: odds ratio [OR]: 13.542; 95% confidence interval [CI]: 3.991-45.950, p<0.001; high-DCP group: OR: 17.853; 95% CI: 4.478-71.179, p<0.001). In the high-AFP group, the 6-month, 12-month, and 18-month PFS and OS rates were higher in the AFP responders than those in the non-responders (PFS: 66.4%, 59.6%, 48.2% vs 42.3%, 19.3%, 0%, p<0.001; OS: 94.5%, 90.4%, 77.3% vs 75.6%, 66.2%, 49.6%, p=0.006). In the high-DCP group, the 6-month, 12-month, and 18-month PFS and OS rates were higher in the DCP responders than those in the non-responders (PFS: 67.4%, 57.7%, 39.0% vs 38.9%, 8.1%, 0%, p<0.001; OS: 94.7%, 94.7%, 83.3% vs 77.0%, 53.9%, 36.0%, p<0.001). Conclusion: After 6 weeks of triple therapy, an AFP or DCP reduction of >50% predicts better treatment outcomes in uHCC patients.